Literature DB >> 26091914

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.

Ekaterina Schreiber-Brynzak1, Erik Klapproth, Christine Unger, Irene Lichtscheidl-Schultz, Simone Göschl, Sarah Schweighofer, Robert Trondl, Helmut Dolznig, Michael A Jakupec, Bernhard K Keppler.   

Abstract

BACKGROUND: Hypoxic and necrotic regions that accrue within solid tumors in vivo are known to be associated with metastasis formation, radio- and chemotherapy resistance, and drug metabolism. Therefore, integration of these tumor characteristics into in vitro drug screening models is advantageous for any reliable investigation of the anticancer activity of novel drug candidates. In general, usage of cell culture models with in vivo like characteristics has become essential in preclinical drug studies and allows evaluation of complex problems such as tumor selectivity and anti-invasive properties of the drug candidates.
MATERIALS AND METHODS: In this study, we investigated the anticancer activity of clinically approved, investigational and experimental drugs based on platinum (cisplatin, oxaliplatin and KP1537), gallium (KP46), ruthenium (KP1339) and lanthanum (KP772) in different cell culture models such as monolayers, multicellular spheroids, as well as invasion and metastasis models. Results Application of the Alamar Blue assay to multicellular spheroids and a spheroid-based invasion assay resulted in an altered rating of compounds with regard to their cytotoxicity and ability to inhibit invasion when compared with monolayer-based cytotoxicity and transwell assays. For example, the gallium-based drug candidate KP46 showed in spheroid cultures significantly enhanced properties to inhibit protrusion formation and fibroblast mediated invasiveness, and improved cancer cell selectivity.
CONCLUSION: Taken together, our results demonstrate the advantages of spheroid-based assays and underline the necessity of using different experimental models for reliable preclinical investigations assessing and better predicting the anticancer potential of new compounds.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091914     DOI: 10.1007/s10637-015-0260-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  48 in total

1.  DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Authors:  Christopher Korch; Monique A Spillman; Twila A Jackson; Britta M Jacobsen; Susan K Murphy; Bruce A Lessey; V Craig Jordan; Andrew P Bradford
Journal:  Gynecol Oncol       Date:  2012-06-16       Impact factor: 5.482

2.  Hypoxia-inducible factor-1α enhances the malignant phenotype of multicellular spheroid HeLa cells in vitro.

Authors:  Xun Tian; Wei Wang; Qinghua Zhang; Liangping Zhao; Junchen Wei; Hui Xing; Yuping Song; Shixuan Wang; Ding Ma; Li Meng; Gang Chen
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

3.  Sphere-forming tumor cells possess stem-like properties in human fibrosarcoma primary tumors and cell lines.

Authors:  Wei-Dong Liu; Tao Zhang; Chun-Lei Wang; Hong-Mei Meng; Yu-Wen Song; Zhe Zhao; Zheng-Min Li; Jiang-Kun Liu; Shang-Ha Pan; Wen-Bo Wang
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

Review 4.  Molecular mechanisms mediating metastasis of hypoxic breast cancer cells.

Authors:  Gregg L Semenza
Journal:  Trends Mol Med       Date:  2012-08-23       Impact factor: 11.951

5.  The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines.

Authors:  Seied Mojtaba Valiahdi; Petra Heffeter; Michael A Jakupec; Rodrig Marculescu; Walter Berger; Klemens Rappersberger; Bernhard K Keppler
Journal:  Melanoma Res       Date:  2009-10       Impact factor: 3.599

Review 6.  Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?

Authors:  Juergen Friedrich; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Int J Radiat Biol       Date:  2007 Nov-Dec       Impact factor: 2.694

7.  {(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo.

Authors:  Sergey A Abramkin; Ute Jungwirth; Seied M Valiahdi; Claudia Dworak; Ladislav Habala; Kristof Meelich; Walter Berger; Michael A Jakupec; Christian G Hartinger; Alexey A Nazarov; Mathea Sophia Galanski; Bernhard K Keppler
Journal:  J Med Chem       Date:  2010-10-28       Impact factor: 7.446

8.  Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

Authors:  Maria Vinci; Sharon Gowan; Frances Boxall; Lisa Patterson; Miriam Zimmermann; William Court; Cara Lomas; Marta Mendiola; David Hardisson; Suzanne A Eccles
Journal:  BMC Biol       Date:  2012-03-22       Impact factor: 7.431

9.  The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.

Authors:  Petra Heffeter; Bihter Atil; Kushtrim Kryeziu; Diana Groza; Gunda Koellensperger; Wilfried Körner; Ute Jungwirth; Thomas Mohr; Bernhard K Keppler; Walter Berger
Journal:  Eur J Cancer       Date:  2013-06-18       Impact factor: 9.162

10.  Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D.

Authors:  Jennifer Laurent; Céline Frongia; Martine Cazales; Odile Mondesert; Bernard Ducommun; Valérie Lobjois
Journal:  BMC Cancer       Date:  2013-02-08       Impact factor: 4.430

View more
  14 in total

Review 1.  Ruthenium(ii)-arene complexes as anti-metastatic agents, and related techniques.

Authors:  Chanchal Sonkar; Sayantan Sarkar; Suman Mukhopadhyay
Journal:  RSC Med Chem       Date:  2021-09-15

2.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

3.  Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.

Authors:  Simone Göschl; Ekaterina Schreiber-Brynzak; Verena Pichler; Klaudia Cseh; Petra Heffeter; Ute Jungwirth; Michael A Jakupec; Walter Berger; Bernhard K Keppler
Journal:  Metallomics       Date:  2017-03-22       Impact factor: 4.526

Review 4.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

Authors:  Nazia Nayeem; Maria Contel
Journal:  Chemistry       Date:  2021-05-05       Impact factor: 5.020

5.  Tumor cells and their crosstalk with endothelial cells in 3D spheroids.

Authors:  Hila Shoval; Adi Karsch-Bluman; Yifat Brill-Karniely; Tal Stern; Gideon Zamir; Ayala Hubert; Ofra Benny
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 6.  Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.

Authors:  Marie Millard; Ilya Yakavets; Vladimir Zorin; Aigul Kulmukhamedova; Sophie Marchal; Lina Bezdetnaya
Journal:  Int J Nanomedicine       Date:  2017-10-31

7.  Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation.

Authors:  Ekaterina Schreiber-Brynzak; Verena Pichler; Petra Heffeter; Buck Hanson; Sarah Theiner; Irene Lichtscheidl-Schultz; Christoph Kornauth; Luca Bamonti; Vineet Dhery; Diana Groza; David Berry; Walter Berger; Markus Galanski; Michael A Jakupec; Bernhard K Keppler
Journal:  Metallomics       Date:  2016-02-10       Impact factor: 4.526

Review 8.  Metallodrugs are unique: opportunities and challenges of discovery and development.

Authors:  Elizabeth J Anthony; Elizabeth M Bolitho; Hannah E Bridgewater; Oliver W L Carter; Jane M Donnelly; Cinzia Imberti; Edward C Lant; Frederik Lermyte; Russell J Needham; Marta Palau; Peter J Sadler; Huayun Shi; Fang-Xin Wang; Wen-Ying Zhang; Zijin Zhang
Journal:  Chem Sci       Date:  2020-11-12       Impact factor: 9.825

9.  Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.

Authors:  Natasja Franceschini; Jan Oosting; Maud Tamsma; Bertine Niessen; Inge Briaire-de Bruijn; Brendy van den Akker; Alwine B Kruisselbrink; Ieva Palubeckaitė; Judith V M G Bovée; Anne-Marie Cleton-Jansen
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

Review 10.  Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy.

Authors:  Vasiliki Gkretsi; Andreas Stylianou; Panagiotis Papageorgis; Christiana Polydorou; Triantafyllos Stylianopoulos
Journal:  Front Oncol       Date:  2015-10-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.